(Reuters) – Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.
Gossamer is to receive $160 million development reimbursement payment and is eligible to receive up to $146 million in regulatory and $180 million in sales milestones as part of the deal.
(Reporting by Christy Santhosh; Editing by Vijay Kishore)
Comments